Home › Research › Drug development
Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?
Gouveri E, Popovic DS, Papanas N.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023-11-11
Topic: Brain proteins, microglia and lab models
Semaglutide is a potent glucagon-like peptide 1 receptor agonist for the management of type 2 diabetes mellitus. In addition to this, it has emerging potential clinical implications. First, there is accumulating preliminary data on its potential role in type 1 diabetes mellitus.
Key findings
- In addition to this, it has emerging potential clinical implications.
- First, there is accumulating preliminary data on its potential role in type 1 diabetes mellitus.
- In this setting, we need to know which patient subgroups may benefit more.
- Furthermore, its role in non-alcoholic fatty liver and in non-alcoholic steatohepatitis is emerging.
Why it matters
This paper concerns semaglutide, a diabetes drug, and its emerging potential clinical implications, including preliminary data in type 1 diabetes. It does not report any finding about treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Diabetes therapy : research, treatment and education of diabetes and related disorders) |
| Journal's citation record | 1 / 4 | Diabetes Therapy: journal h-index 77 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 15 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.8 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Νικόλαος Παπάνας: h-index 57 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Democritus University of Thrace: institution h-index 289 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37950798) |
| Free to read | 2 / 2 | Free to read |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s13300-023-01506-1
- PubMed: 37950798
- Original source →
- Free full text: Diabetes Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Gouveri, E., Popovic, D. S., & Papanas, N. (2024). Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow? Diabetes therapy : research, treatment and education of diabetes and related disorders. https://doi.org/10.1007/s13300-023-01506-1
Vancouver
Gouveri E, Popovic DS, Papanas N. Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow? Diabetes therapy : research, treatment and education of diabetes and related disorders. 2024. doi:10.1007/s13300-023-01506-1. PMID: 37950798.
BibTeX
@article{gouveri2024-37950798,
author = {Gouveri, E. and Popovic, D. S. and Papanas, N.},
title = {{Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?}},
journal = {Diabetes therapy : research, treatment and education of diabetes and related disorders},
year = {2024},
doi = {10.1007/s13300-023-01506-1},
pmid = {37950798},
url = {https://doi.org/10.1007/s13300-023-01506-1}
}
Related studies in Drug development
Also in Drug development
79 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.